In the news release, Concept Matrix Solutions Receives Patent
Approval for its Oral Soft Gel Capsule Containing Psychedelic
Compound, issued 13-Aug-2024 by
CONCEPT MATRIX SOLUTIONS over PR Newswire, we are advised by the
company that information pertaining to XYZ Pharmaceuticals that was
erroneously included should not be present. The complete, corrected
release follows:
Concept Matrix Solutions Receives Patent Approval for its Oral Soft
Gel Capsule Containing Psychedelic Compound
THOUSAND
OAKS, Calif., Aug. 13,
2024 /PRNewswire/ -- Concept Matrix Solutions, Inc.
("CMS") or the ("Company"), a privately held vertically integrated
biotechnology company dedicated to developing and manufacturing
innovative delivery forms in both pharmaceutical and nutraceutical
spaces today announced that it has received patent issuance from
the U.S. Patent Office (USPTO) regarding U.S. Patent No. 11,766,445
for its "Oral Soft Gel Capsule Containing Psychedelic Compound".
This patent marks a significant milestone in the company's efforts
to develop more effective treatments for mental health disorders
and chronic pain conditions.
Concept Matrix Solutions, Inc. Receives
Patent Approval for its Oral Soft Gel Capsule Containing
Psychedelic Compound.
The newly patented soft gel capsule technology offers several
advantages over traditional delivery methods which allows for
improved rate and extent of absorption, and the reduced variability
per dosage, potentially leading to more consistent and effective
dosing. Furthermore, encapsulation process helps protect the
psychedelic compound from degradation, potentially extending shelf
life and maintaining potency. Soft gel capsules are easy to swallow
and can be taken discreetly, improving patient compliance and
comfort.
Rob Davidson, Chief Technology
Officer at CMS, commented on the patent issuance: "This new
delivery method represents a significant advancement in psychedelic
medicine. By improving bioavailability and ease of use, we believe
our soft gel capsules will help more patients benefit from the
therapeutic potential of psychedelics."
The development of novel dose forms for psychedelic compounds
comes at a critical time, as mental health disorders and chronic
pain conditions continue to affect millions of people worldwide.
Recent studies have shown promising results for the use of
psychedelics in treating anxiety, post-traumatic stress disorder
(PTSD), obsessive-compulsive disorder (OCD), and various forms of
chronic pain.
Tony LaRosa, Chief Executive
Officer at CMS, commented, "There is an urgent need for more
effective treatments for these challenging conditions, traditional
pharmaceuticals often fall short in providing long-lasting relief,
and many patients struggle with side effects or develop tolerance.
Our research suggests that psychedelic compounds, when properly
administered, may offer a new paradigm in mental health and pain
management."
View original content to download
multimedia:https://www.prnewswire.com/news-releases/concept-matrix-solutions-receives-patent-approval-for-its-oral-soft-gel-capsule-containing-psychedelic-compound-302221287.html
SOURCE CONCEPT MATRIX SOLUTIONS